Actually ADHD | Medication Strategies & Clinical Wisdom

Jonathan Murphy, PMHNP-BC
  • 5.0 (2)
  • Medicine

Adult ADHD from the board-certified PMHNP behind the YouTube channel Focus Path and the book The Process. Clinical perspective on medication, frameworks, and the conversations the internet hasn't been having.

  1. 19h ago

    Paris Hilton’s ADHD Moment Was Paid For By Big Pharma (How I Know)

    The companion podcast to the video that is making waves on the Focus Path YouTube channel. Jonathan Murphy, PMHNP-BC, breaks down the pharmaceutical pipeline behind Paris Hilton’s ADHD advocacy, tells the Disney World story he has never told publicly before, and names the creators who attended the Collegium-funded mansion party. Paris Hilton hosted 200 influencers at her Beverly Hills mansion for the Unstoppable ADHD Creator Summit. Every major media outlet covered it. Every outlet mentioned the same drug by name: Jornay PM. Nobody asked why. In 2025, a press release said it plainly. Paris Hilton collaborates with Collegium Pharmaceutical to share her personal ADHD journey and experience with treatment. Collegium makes Jornay PM. Jornay PM is projected to bring in $200 million this year. This episode covers the Hilton family fortune and why it was given to charity twice, the rebrand from The Simple Life to Embrace Your Sparkle, the five talking points that repeat across every media outlet, the Anti-Kickback Statute and why there is no law for the celebrity loophole, pharma dinners and what they are actually like from the inside, the Shire Disney World story, the Ironshore origin of Jornay PM, the payment map from Collegium to Paris to the nonprofit to the creators to the audience, and why the superpower language is everything we do not want mental health to be. Watch the video: https://www.youtube.com/watch?v=JExWhZxrRJw Read the article: https://www.myfocuspath.blog/p/paris-hilton-jornay-pm-and-modern The Process: An Adult’s Guide to ADHD Medication, available on Amazon Focus Path YouTube Channel: @FocusPathSystems X (Twitter): @ADHDAuthority

  2. 1d ago

    Simtriyo (Centanafadine): A Prescriber’s Honest Take on the New ADHD Medication

    The DEA just scheduled centanafadine as Schedule III. The internet is about to lose its mind over this one. Jonathan Murphy, PMHNP-BC, breaks it down before the marketing noise drowns out the clinical reality. Simtriyo is a new ADHD medication approved by the FDA in July 2026, now scheduled by the DEA as of October 30, 2026. It is being marketed as a first-in-class triple reuptake inhibitor hitting norepinephrine, dopamine, and serotonin. The binding data tells a different story. The serotonin piece is likely not clinically relevant at therapeutic doses. The effect size is roughly one-third of traditional stimulants. No head-to-head trial against any existing ADHD medication was ever conducted. Two black box warnings: abuse potential and suicidality. This episode covers what Schedule III actually means versus Schedule II, how Otsuka Pharmaceutical developed the drug, why the triple reuptake inhibitor label is marketing language, why the serotonin claim is unproven, the abuse potential data from primate self-administration studies, why the suicidality warning matters for patients with mood instability, and why the honest clinical recommendation is to wait a year. The Process: An Adult’s Guide to ADHD Medication, available on Amazon Focus Path YouTube Channel: @FocusPathSystems X (Twitter): @ADHDAuthority

  3. 2d ago

    Reflections on ADHD, and Media: OCPD, The General, and Why Men and Women Aren’t That Different

    Jonathan Murphy, PMHNP-BC, goes deep on the difference between ADHD and obsessive compulsive personality disorder, why the online ADHD conversation has gotten it wrong, and why men and women with ADHD are far more alike than the internet wants you to believe. This episode covers the three waves of ADHD content creators: the first wave of actual clinicians like Dr. Tracey Marks, the second wave of TikTok docs post-COVID, and what comes next. A direct critique of Dr. Sasha Hamdani’s identity-driven ADHD content and Ruri Ohama’s medication cessation narrative, and why personal storytelling about your own symptoms is not clinical education. The OCPD-ADHD overlap explained: the interruption in focus, the hyperfocus-crash cycle, unrealistic standards, perfectionism as relative safety, and why the core pathology matters more than the label. Egodystonic versus egosyntonic. Why the comorbidity question is always there. An introduction to the Survival Modality system through The General: the rage-shame cycle, the road rage archetype, why a female general and a male general carry the same attachment wound differently, and why the gender conversation misses the point that men and women share more inner experience than not. The episode ends where it began: regulate before you navigate. ADHD medication gets the brain online. Everything after that is the real work.

  4. 2d ago

    ADHD in the Internet Age: Media Literacy, Guanfacine, and the Loop

    Paris Hilton’s ADHD grift. Guanfacine’s quiet substitution for stimulants. The search term economy. The tribal internet. In this episode, Jonathan Murphy, PMHNP-BC, connects the dots between what’s happening online and what’s happening in his office. The internet created a two-way signal. Your search terms are the raw material of a new economy. The demand for ADHD content created a virtual gold rush of creators rushing to meet it, and most of them have never prescribed a medication. Meanwhile, the platforms lock you into parasocial loops, tribalize your diagnosis, and commodify your identity. This episode covers why ADHD without stimulant medication is all fluff, why guanfacine is being propped up internationally as a substitute that does not treat core ADHD symptoms, why the newly diagnosed adult needs to be approached differently, why the diagnosis is not absolution, and why the goal of this podcast is for you to not need it anymore. Also discussed: the phone as passive multimedia, Neil Postman’s Amusing Ourselves to Death, Reddit as the worst place to learn, the commodification of identity, and why the beginning of the loop is the search term you typed. New video: Paris Hilton Was Never Dumb — That’s Why You Should Be Worried About Her ADHD Campaign. Link in show notes. The Process: An Adult’s Guide to ADHD Medication, available on Amazon Focus Path YouTube Channel: @FocusPathSystems X (Twitter): @ADHDAuthority

  5. Oct 30

    Indirect Communication in the Online ADHD Era: The Director’s Cut

    The companion episode to the LEARNARAMA video “What You Need To Break Everything Wrong With The Internet.” Jonathan Murphy, PMHNP-BC, breaks down the structural argument of the video in real time, walking through the narrative from direct communication to the loop that keeps you scrolling. This episode covers the creative journey of making the video, the origins of the Learn-O-Rama series and the retro futurism of mid-century public education films, and why the channel looks and feels different from everything else in the ADHD space. The structural breakdown: direct communication has always produced a biological response, from a handwritten letter on the Pony Express to a DM on Bumble. Indirect communication has always shaped your fate, from Greek theater to the printing press to corporate broadcasting. But smartphones created the first two-way signal. Now every swipe, click, grimace, and maybe even vocalization produces a return signal aimed at maximizing the extraction of economic value from your attention. Search terms are the new supply and demand. YouTube is the new mainstream. And the mainstream is filled with anti-psychiatry physicians, wellness bros slinging supplements, Instagram influencers monetizing their medication experience, and TikTok docs thrust into the spotlight on a whim. Meanwhile corporate healthcare monoliths can hardly be bothered to make content. Nice try though. Educational content can be entertaining and informative. When the demand is met, the search terms reduce, and the flywheel slows down. That is the hope. That is Focus Path. The Process: An Adult’s Guide to ADHD Medication, available on Amazon Focus Path YouTube Channel: @FocusPathSystems X (Twitter): @ADHDAuthority

  6. Oct 28

    H3H3’s Collapse and the Parasocial Era of YouTube: A Psychiatric Nurse Practitioner’s Take

    As the H3 Podcast goes on indefinite hiatus, psychiatric nurse practitioner Jonathan Murphy, PMHNP-BC, looks at the era of YouTube that H3H3 came to define. It started with short films and creative experiments like Angry Video Game Nerd and “Vape Nation” and became talking heads, podcasts, and parasocial engagement. He grew up alongside YouTube, and here he looks at what the platform rewards now, why licensed medical content gets labeled high risk, and what your attention is worth. This episode covers the difference between parasocial and prosocial relationships, why engagement-driven content keeps you watching without adding to your life, and how to judge what you get from the creators you follow. This episode covers: ▸ Getting rid of the smartphone in 2019 and coming back online to teach ▸ Growing up alongside YouTube ▸ Why medication content gets flagged as high risk while unlicensed influencers don’t ▸ Engagement versus education: what the algorithm rewards ▸ Parasocial versus prosocial: why he answers questions one-on-one ▸ Being a platform-native creator: clinical education made as short films ▸ TikTok docs and the low barrier to entry ▸ The podcast boom and the economics of AI slop ▸ H3H3: from Vape Nation to the H3 Podcast’s collapse ▸ Performed authority versus real authority ▸ Internet culture as the new mainstream media ▸ Parasocial communities, rejection sensitivity, and empty connection ▸ Smartphones, passive engagement, and your brain ▸ Your clicks and attention are worth more than you realize Find Jonathan on X @ADHDAuthority, or on YouTube at Focus Path Systems. 📕 The Process: An Adult’s Guide to ADHD Medication: https://www.amazon.com/dp/B0H2Z6PM4T 📗 Cheat Codes: https://www.amazon.com/dp/B0FMJLQKBW ⚠️ Educational purposes only. Not medical advice, and no clinical relationship is established by listening. Never start, stop, or change a medication without your prescriber. If you are in crisis, call or text 988. Jonathan Murphy, PMHNP-BC | Focus Path Licensed in MA, NH, WA, OR | NPI 1821441965 Board Certified | ANCC 2017007119 CHADD Professional Member | ADDitude Professional Directory 🎥 https://www.youtube.com/@focuspathsystems 𝕏 @ADHDAuthority 🔗 https://myfocuspath.com 🔗 https://www.myfocuspath.blog 📧 https://mailchi.mp/myfocuspath/focus-path-pmhnp

  7. Oct 27

    Prescriber Toolkit: Methylphenidate, How to Start and When to Switch (Ritalin LA, Metadate CD, Concerta, Jornay PM, Focalin)

    The first edition of the Prescriber Toolkit. Psychiatric nurse practitioner Jonathan Murphy, PMHNP-BC, walks through methylphenidate the way he uses it in practice: where to start, how to judge a trial, when to raise the dose, and when to move to a different formulation. It opens with the bigger picture: the massive search demand for real-world ADHD medication information, the loop of grifters, pseudoscience, and engagement algorithms that fills it, and why receptor-level debates can lose the plot. Then the toolkit: Ritalin LA, Concerta, Metadate CD, Jornay PM, Focalin, Aptensio, and Azstarys, plus alcohol and methylphenidate. This episode covers: ▸ Holding the frame: real-world impact on the patient ▸ Unmet demand: why “what do I do on my first day of Vyvanse?” goes unanswered ▸ The loop: grifters, wellness pseudoscience, Reddit, and engagement algorithms ▸ The SimCity analogy: psychopharmacology without losing the forest for the trees ▸ Neurons, synapses, and dopamine “buttons,” in plain language ▸ Methylphenidate versus amphetamine: why methylphenidate is less stimulating ▸ Who might start on methylphenidate: anxiety, autism, or overstimulation on amphetamines ▸ Ritalin LA 20 mg or Concerta 36 mg as a starting point, and how Concerta’s tablet differs ▸ Metadate CD for longer duration, and dosing up to 60 mg ▸ When to increase the dose: duration, tiredness, partial response ▸ Why the first week isn’t the test: give a trial a month ▸ Jornay PM: the nighttime dose, and why the milligrams don’t compare directly ▸ Focalin (dexmethylphenidate): when it’s the one that finally works ▸ Aptensio and Azstarys: why the ratios don’t matter much and availability does ▸ Alcohol and methylphenidate: why to avoid the combination ▸ How ADHD medication can curb the stimulation-seeking behind substance use New on YouTube: the Rx Info installment on Vyvanse. Search @FocusPathSystems. Questions: X @ADHDAuthority. 📕 The Process: An Adult’s Guide to ADHD Medication: https://www.amazon.com/dp/B0H2Z6PM4T 📗 Cheat Codes: https://www.amazon.com/dp/B0FMJLQKBW ⚠️ Educational purposes only. Not medical advice, and no clinical relationship is established by listening. Never start, stop, or change a medication without your prescriber. If you are in crisis, call or text 988. Jonathan Murphy, PMHNP-BC | Focus Path Licensed in MA, NH, WA, OR | NPI 1821441965 Board Certified | ANCC 2017007119 CHADD Professional Member | ADDitude Professional Directory 🎥 https://www.youtube.com/@focuspathsystems 𝕏 @ADHDAuthority 🔗 https://myfocuspath.com 🔗 https://www.myfocuspath.blog 📧 https://mailchi.mp/myfocuspath/focus-path-pmhnp

  8. Oct 26

    Why My ADHD Perspective Is So Rare: From Psych Unit Counselor to ADHD Prescriber

    Actually ADHD is ranked #1 on Apple Podcasts and Spotify for ADHD medication. In this episode, Jonathan Murphy, PMHNP-BC, tells the story behind the perspective: crashing out at 22, taking a job for the health insurance, and working his way from counselor on an adult inpatient psych unit at Pembroke Hospital to nurse on the child and adolescent psychiatry unit at Boston Children’s Hospital, then to psychiatric mental health nurse practitioner at an ADHD clinic. He explains why he left inpatient psychiatry and pediatrics to treat adults only, how a psychiatric nurse practitioner’s training shapes the way he talks about ADHD medication, and why he doesn’t present himself as the authority figure common on physician-led podcasts. Having taken ADHD medication himself through adolescence and adulthood, he describes learning that ADHD medication treatment is less about the drug and more about the individual: the right medication, for the right person, for the right reason. The episode also introduces Rx Info, his YouTube series of in-depth medication reviews covering manufacturing, FDA regulation, track record and clinical use, with a new episode on Vyvanse (lisdexamfetamine). It previews the Prescriber’s Toolkit, an upcoming podcast series for patients and clinicians on how ADHD medications like methylphenidate are used in real practice. Educational content only. This podcast does not provide medical advice. Talk with your own prescriber before starting, stopping or changing any medication. YouTube: @FocusPathSystems | X: @ADHDAuthority

See All (49)

Ratings & Reviews

5
out of 5
2 Ratings

About

Adult ADHD from the board-certified PMHNP behind the YouTube channel Focus Path and the book The Process. Clinical perspective on medication, frameworks, and the conversations the internet hasn't been having.

Information

  • Creator
    Jonathan Murphy, PMHNP-BC
  • Years Active
    2026
  • Episodes
    49
  • Rating
    Clean
  • Copyright
    © 2026 Focus Path Systems

You Might Also Like